• Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=11115575).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (PubMed=11115575).
  

PubMed=7804431; DOI=10.1111/j.1440-1827.1994.tb02948.x
Sugiura H., Ishikura H., Omi M., Kaji M., Iwai K., Kishimoto T., Takahashi T., Kimura C., Kato H., Yoshiki T.
Lymphokine-activated killer cytotoxicity against pancreas adenocarcinoma cell lines and vascular endothelial cells.
Pathol. Int. 44:688-696(1994)

PubMed=8797870; DOI=10.1002/(SICI)1097-0215(19960822)69:4<290::AID-IJC9>3.0.CO;2-S
Kishimoto T., Ishikura H., Kimura C., Takahashi T., Kato H., Yoshiki T.
Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen.
Int. J. Cancer 69:290-294(1996)

PubMed=11115575; DOI=10.3892/or.8.1.89
Sun C.-L., Yamato T., Furukawa T., Ohnishi Y., Kijima H., Horii A.
Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.
Oncol. Rep. 8:89-92(2001)